A bill to ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care.

S. 4027, the 'Healthy Competition for Better Care Act,' was introduced in the Senate on March 9, 2026, by Senator Husted [R-OH] and subsequently referred to the Committee on Health, Education, Labor, and Pensions. The bill's core objective is to ban anticompetitive terms in facility and insurance contracts that restrict health plans' network design flexibility, such as directing participants to specific providers or requiring agreements with affiliates. This legislation is currently in the early stages of the legislative process, having only been introduced and referred to committee. The bill does not authorize or appropriate any specific funding amount. Instead, its mechanism for market impact is regulatory: it directly prohibits certain contractual clauses that limit competition. By doing so, it aims to empower health insurance companies to negotiate more favorable terms with healthcare providers, potentially leading to lower costs for services. This regulatory relief is intended to foster greater price transparency and competition within the healthcare provider market, which would indirectly benefit health insurers by reducing their payouts for services. Structural winners under this proposed legislation would be health insurance providers, including companies like The Cigna Group ($CI), Humana Inc. ($HUM), and CVS Health Corporation ($CVS), which operates Aetna. These companies stand to gain increased leverage in negotiations with healthcare facilities and providers, potentially leading to reduced operational costs and improved profit margins. Conversely, healthcare providers and facilities that currently benefit from anticompetitive clauses could face increased pressure on their pricing and contract terms. The bill's early stage means that its ultimate passage and implementation are not guaranteed, and the timeline for further legislative action is uncertain, depending on committee review and potential floor votes. Examining recent market data, The Cigna Group ($CI) is trading at $275.69, showing a 7-day change of +6.82%. Humana Inc. ($HUM) is at $182.65, with a significant 7-day increase of +10.03%. CVS Health Corporation ($CVS) is at $73.28, reflecting a 7-day change of +4.48%. These positive short-term movements suggest that the market is reacting favorably to the potential for regulatory changes that could benefit health insurers, despite the bill's early legislative stage. However, the 30-day changes for $CI (-1.98%) and $CVS (-6.88%) indicate that the recent positive momentum is a short-term trend, while $HUM has a modest 30-day gain of +1.05%.